Company / Cash & Equivalents
NOVAVAX INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$240.6M
FY2025
5-year range
$240.6M / $1.5B
FY2021-FY2025
Trend
-54.6%
vs FY2024
Sector context
#71 of 207
Health Care
What the data says
At $241M, NOVAVAX INC's cash & equivalents ranks #71 of 207 in the Health Care sector. Cash & Equivalents has declined for 3 consecutive years, from $1.5B in FY2022 to $241M in FY2025.
Based on SEC 10-K filings.
$241M in FY2025 with a 5-year CAGR of -15.3%.
Declined from $569M to $241M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -45.8%
- 5-Year CAGR
- -15.3%
- 10-Year CAGR
- -
Sector benchmark
#71 of 207 in Health CareTop 34% of 207This company $240.6M Sector average $669.5M
▼
-64.1% below sector average
Key checks
Key Insights
- NOVAVAX INC's cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -15.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 54.6% year-over-year.
- Ranks #71 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $240.6M | -54.6% |
| FY2024 | $530.2M | -6.7% |
| FY2023 | $568.5M | -62.5% |
| FY2022 | $1.5B | +0.0% |
| FY2021 | $1.5B | +173.8% |
| FY2020 | $553.4M | +602.1% |
| FY2019 | $78.8M | +12.4% |
| FY2018 | $70.2M | -34.0% |
| FY2017 | $106.3M | +228.8% |
| FY2016 | $32.3M | -72.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026